PREMAS Biotech Launches its Range of Human Drug Metabolism Enzymes
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
PREMAS Biotech launches its suite of recombinant Human Cytochrome P450 Isozymes expressed in Saccharomyces cerevisiae. These Microsomes contain human CYP450 isozyme and human NADPH oxido reductase hence offering higher specific activity and performance.
These Isozymes will be expressed in Yeast which means that these recombinant human enzymes mimic their native forms and Ensures biological and pharmacologically active isoforms. PREMAS will be using their Proprietary vectors for optimized expression.
These Isozymes will be expressed in Yeast which means that these recombinant human enzymes mimic their native forms and Ensures biological and pharmacologically active isoforms. PREMAS will be using their Proprietary vectors for optimized expression.
